Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes

Hermes J Florez, Jiacong Luo, Sumaya Castillo-Florez, Georgia Mitsi, John Hanna, Leonardo Tamariz, Ana M Palacio, Sukumar Nagendran, Michael Hagan

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Aims: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). This study assesses the impact of 1) metformin on GI symptoms and health-related quality of life (HRQoL) and 2) metformin-associated GI symptoms on medication adherence in patients with type 2 diabetes newly beginning therapy. Methods: Patients with T2DM aged ≥ 18 years starting metformin from January to June 2007 who fi lled their prescriptions for ≥ 3 months were identifi ed from a health benefi ts company database. Via telephone, GI symptom impact was evaluated in a 360-patient sample using the validated Bowel Symptom Questionnaire and Medical Outcomes Study 36-Item Short-Form Health (SF-36) survey. Adherence was assessed using the medication possession ratio (MPR). Logistic regression adjusting for demographic and clinical covariates was used to assess the relationship between GI symptoms and MPR < 80%. Results: The most and least common GI symptoms reported were diarrhea (62.1%) and retching (21.1%), respectively. Most GI symptoms were associated with lower physical and mental HRQoL (P < 0.05). Most changes in specifi c HRQoL reached the minimum important difference of 3 points. Bloating, nausea, and abdominal pain were signifi cantly associated with MPR < 80%. Adjustment for demographic, clinical, and HRQoL factors made these relationships less evident. Conclusions: Metformin-associated GI symptoms in patients with T2DM lead to lower physical and mental HRQoL, which may result in patient nonadherence or physician reluctance to optimally titrate the metformin dose.

Original languageEnglish
Pages (from-to)112-120
Number of pages9
JournalPostgraduate Medicine
Volume122
Issue number2
DOIs
StatePublished - Mar 1 2010

Fingerprint

Metformin
Patient Compliance
Type 2 Diabetes Mellitus
Quality of Life
Mental Health
Demography
Medication Adherence
Health
Telephone
Nausea
Abdominal Pain
Prescriptions
Diarrhea
Logistic Models
Outcome Assessment (Health Care)
Databases
Physicians
Surveys and Questionnaires

Keywords

  • Adherence
  • Health-related quality of life
  • Metformin
  • Type 2 diabetes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. / Florez, Hermes J; Luo, Jiacong; Castillo-Florez, Sumaya; Mitsi, Georgia; Hanna, John; Tamariz, Leonardo; Palacio, Ana M; Nagendran, Sukumar; Hagan, Michael.

In: Postgraduate Medicine, Vol. 122, No. 2, 01.03.2010, p. 112-120.

Research output: Contribution to journalArticle

Florez, Hermes J ; Luo, Jiacong ; Castillo-Florez, Sumaya ; Mitsi, Georgia ; Hanna, John ; Tamariz, Leonardo ; Palacio, Ana M ; Nagendran, Sukumar ; Hagan, Michael. / Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. In: Postgraduate Medicine. 2010 ; Vol. 122, No. 2. pp. 112-120.
@article{dd02d9dfc427453a935a1e27c16e56dc,
title = "Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes",
abstract = "Aims: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). This study assesses the impact of 1) metformin on GI symptoms and health-related quality of life (HRQoL) and 2) metformin-associated GI symptoms on medication adherence in patients with type 2 diabetes newly beginning therapy. Methods: Patients with T2DM aged ≥ 18 years starting metformin from January to June 2007 who fi lled their prescriptions for ≥ 3 months were identifi ed from a health benefi ts company database. Via telephone, GI symptom impact was evaluated in a 360-patient sample using the validated Bowel Symptom Questionnaire and Medical Outcomes Study 36-Item Short-Form Health (SF-36) survey. Adherence was assessed using the medication possession ratio (MPR). Logistic regression adjusting for demographic and clinical covariates was used to assess the relationship between GI symptoms and MPR < 80{\%}. Results: The most and least common GI symptoms reported were diarrhea (62.1{\%}) and retching (21.1{\%}), respectively. Most GI symptoms were associated with lower physical and mental HRQoL (P < 0.05). Most changes in specifi c HRQoL reached the minimum important difference of 3 points. Bloating, nausea, and abdominal pain were signifi cantly associated with MPR < 80{\%}. Adjustment for demographic, clinical, and HRQoL factors made these relationships less evident. Conclusions: Metformin-associated GI symptoms in patients with T2DM lead to lower physical and mental HRQoL, which may result in patient nonadherence or physician reluctance to optimally titrate the metformin dose.",
keywords = "Adherence, Health-related quality of life, Metformin, Type 2 diabetes",
author = "Florez, {Hermes J} and Jiacong Luo and Sumaya Castillo-Florez and Georgia Mitsi and John Hanna and Leonardo Tamariz and Palacio, {Ana M} and Sukumar Nagendran and Michael Hagan",
year = "2010",
month = "3",
day = "1",
doi = "10.3810/pgm.2010.03.2128",
language = "English",
volume = "122",
pages = "112--120",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "2",

}

TY - JOUR

T1 - Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes

AU - Florez, Hermes J

AU - Luo, Jiacong

AU - Castillo-Florez, Sumaya

AU - Mitsi, Georgia

AU - Hanna, John

AU - Tamariz, Leonardo

AU - Palacio, Ana M

AU - Nagendran, Sukumar

AU - Hagan, Michael

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Aims: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). This study assesses the impact of 1) metformin on GI symptoms and health-related quality of life (HRQoL) and 2) metformin-associated GI symptoms on medication adherence in patients with type 2 diabetes newly beginning therapy. Methods: Patients with T2DM aged ≥ 18 years starting metformin from January to June 2007 who fi lled their prescriptions for ≥ 3 months were identifi ed from a health benefi ts company database. Via telephone, GI symptom impact was evaluated in a 360-patient sample using the validated Bowel Symptom Questionnaire and Medical Outcomes Study 36-Item Short-Form Health (SF-36) survey. Adherence was assessed using the medication possession ratio (MPR). Logistic regression adjusting for demographic and clinical covariates was used to assess the relationship between GI symptoms and MPR < 80%. Results: The most and least common GI symptoms reported were diarrhea (62.1%) and retching (21.1%), respectively. Most GI symptoms were associated with lower physical and mental HRQoL (P < 0.05). Most changes in specifi c HRQoL reached the minimum important difference of 3 points. Bloating, nausea, and abdominal pain were signifi cantly associated with MPR < 80%. Adjustment for demographic, clinical, and HRQoL factors made these relationships less evident. Conclusions: Metformin-associated GI symptoms in patients with T2DM lead to lower physical and mental HRQoL, which may result in patient nonadherence or physician reluctance to optimally titrate the metformin dose.

AB - Aims: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). This study assesses the impact of 1) metformin on GI symptoms and health-related quality of life (HRQoL) and 2) metformin-associated GI symptoms on medication adherence in patients with type 2 diabetes newly beginning therapy. Methods: Patients with T2DM aged ≥ 18 years starting metformin from January to June 2007 who fi lled their prescriptions for ≥ 3 months were identifi ed from a health benefi ts company database. Via telephone, GI symptom impact was evaluated in a 360-patient sample using the validated Bowel Symptom Questionnaire and Medical Outcomes Study 36-Item Short-Form Health (SF-36) survey. Adherence was assessed using the medication possession ratio (MPR). Logistic regression adjusting for demographic and clinical covariates was used to assess the relationship between GI symptoms and MPR < 80%. Results: The most and least common GI symptoms reported were diarrhea (62.1%) and retching (21.1%), respectively. Most GI symptoms were associated with lower physical and mental HRQoL (P < 0.05). Most changes in specifi c HRQoL reached the minimum important difference of 3 points. Bloating, nausea, and abdominal pain were signifi cantly associated with MPR < 80%. Adjustment for demographic, clinical, and HRQoL factors made these relationships less evident. Conclusions: Metformin-associated GI symptoms in patients with T2DM lead to lower physical and mental HRQoL, which may result in patient nonadherence or physician reluctance to optimally titrate the metformin dose.

KW - Adherence

KW - Health-related quality of life

KW - Metformin

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=77950346254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950346254&partnerID=8YFLogxK

U2 - 10.3810/pgm.2010.03.2128

DO - 10.3810/pgm.2010.03.2128

M3 - Article

C2 - 20203462

AN - SCOPUS:77950346254

VL - 122

SP - 112

EP - 120

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 2

ER -